In R/R non-Hodgkin lymphoma (NHL) patients, CD19-CAR therapy achieved 40–90% of CR in heavily pretreated patients as reported by some of the main clinical assay JULIET [34], ZUMA-1 [35], and TRANSCEND NHL 001 [36]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.